![Western Blot: mu Opioid R/OPRM1 Antibody [NBP1-31180] - Sample(30 ug of whole cell lysate) A:A431 B:H1299 7.5% SDS PAGE, antibody diluted at 1:500.](http://images.novusbio.com/fullsize/mu-Opioid-R-OPMR1-Antibody-Western-Blot-NBP1-31180-img0006.jpg "Western Blot: mu Opioid R/OPRM1 Antibody [NBP1-31180] - Sample(30 ug of whole cell lysate) A:A431 B:H1299 7.5% SDS PAGE, antibody diluted at 1:500.")
| Reactivity | Hu, RMSpecies Glossary |
| Applications | WB, Flow, ICC/IF, IHC |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Immunogen | Carrier-protein conjugated synthetic peptide encompassing a sequence within the N-terminus region of human mu Opioid R/OPRM1. The exact sequence is proprietary. |
| Localization | Cell membrane, Multi-pass membrane protein |
| Predicted Species | Rhesus Macaque (93%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | OPRM1 |
| Purity | Antigen Affinity-purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Theoretical MW | 45 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| Reviewed Applications |
|
|
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS, 1% BSA, 20% Glycerol |
| Preservative | 0.01% Thimerosal |
| Purity | Antigen Affinity-purified |
| Images | Ratings | Applications | Species | Date | Details | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Enlarge |
reviewed by:
Verified Customer |
WB | Rat | 02/21/2015 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for mu Opioid R/OPRM1 Antibody (NBP1-31180)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | OPRM1 |
![Immunocytochemistry/Immunofluorescence: mu Opioid R/OPRM1 Antibody [NBP1-31180] - MOR immunofluorescence in human astrocytes and microglia. MOR and GFAP co-localization in subsets of primary human astrocytes (C) immunofluorescence in subpopulations of primary human microglia (ScienCell; catalog number 1900-f1) cultured as described for astrocytes. Cells were fixed with 3.7% paraformaldehyde, permeabilized with 0.5% Triton X-100, immuno-labeled, nuclei were stained with DAPI (blue). Primary antibodies used at a 1:200 dilution. Images were acquired using a Zeiss LSM 700 laser scanning confocal microscope at 63x (1.42 NA) magnification and ZEN 2010 software (Carl Zeiss Inc, Thornwood, NY), and edited using ZEN 2009 Light Edition (Zeiss) and Adobe Photoshop CS3 Extended 10.0 software (Adobe Systems, Inc.). Image collected and cropped by CiteAb from the following publication (pubmed.ncbi.nlm.nih.gov/22591368/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/mu-Opioid-R-OPRM1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31180-img0007.jpg "Immunocytochemistry/Immunofluorescence: mu Opioid R/OPRM1 Antibody [NBP1-31180] - MOR immunofluorescence in human astrocytes and microglia. MOR and GFAP co-localization in subsets of primary human astrocytes (C) immunofluorescence in subpopulations of primary human microglia (ScienCell; catalog number 1900-f1) cultured as described for astrocytes. Cells were fixed with 3.7% paraformaldehyde, permeabilized with 0.5% Triton X-100, immuno-labeled, nuclei were stained with DAPI (blue). Primary antibodies used at a 1:200 dilution. Images were acquired using a Zeiss LSM 700 laser scanning confocal microscope at 63x (1.42 NA) magnification and ZEN 2010 software (Carl Zeiss Inc, Thornwood, NY), and edited using ZEN 2009 Light Edition (Zeiss) and Adobe Photoshop CS3 Extended 10.0 software (Adobe Systems, Inc.). Image collected and cropped by CiteAb from the following publication (pubmed.ncbi.nlm.nih.gov/22591368/), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: mu Opioid R/OPRM1 Antibody [NBP1-31180] - Cal27 xenograft, using mu Opioid receptor antibody at 1:500 dilution.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/mu-Opioid-R-OPMR1-Antibody-Immunohistochemistry-Paraffin-NBP1-31180-img0005.jpg "Immunohistochemistry-Paraffin: mu Opioid R/OPRM1 Antibody [NBP1-31180] - Cal27 xenograft, using mu Opioid receptor antibody at 1:500 dilution.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.")
![Western Blot: mu Opioid R/OPRM1 Antibody [NBP1-31180] - E2 & G-1 stimulate phosphorylation of MOR in a PKC-dependent manner. (A,B) SH-SY5Y cells treated with PMA (1 μM), E2 (1 μM), or G-1 (1 μM) for 30 min showed increased level of phosphorylated MOR (pMOR) as compared with the vehicle group. In the presence of the pan-PKC inhibitor (Ro 31-8820, Ro, 3 μM), E2 & G-1 failed to increase pMOR expression. (C) The averaged pMOR level (relative to beta -actin) in cells with different treatments. After detection of pMOR (A,B), the nitrocellulose membrane was stripped & re-blocked by 5% fat-free dry milk in TBST, followed by incubation with MOR primary antibody, then MOR band was detected. ∗∗P < 0.01, ∗∗∗P < 0.001, one-way ANOVA with Tukey’s post hoc test, averaged data from three to four independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31920512), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31180_rabbit-polyclonal-mu-opioid-r-oprm1-antibody-310202415363716.jpg "Western Blot: mu Opioid R/OPRM1 Antibody [NBP1-31180] - E2 & G-1 stimulate phosphorylation of MOR in a PKC-dependent manner. (A,B) SH-SY5Y cells treated with PMA (1 μM), E2 (1 μM), or G-1 (1 μM) for 30 min showed increased level of phosphorylated MOR (pMOR) as compared with the vehicle group. In the presence of the pan-PKC inhibitor (Ro 31-8820, Ro, 3 μM), E2 & G-1 failed to increase pMOR expression. (C) The averaged pMOR level (relative to beta -actin) in cells with different treatments. After detection of pMOR (A,B), the nitrocellulose membrane was stripped & re-blocked by 5% fat-free dry milk in TBST, followed by incubation with MOR primary antibody, then MOR band was detected. ∗∗P < 0.01, ∗∗∗P < 0.001, one-way ANOVA with Tukey’s post hoc test, averaged data from three to four independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31920512), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: mu Opioid R/OPRM1 Antibody [NBP1-31180] - E2 & G-1 stimulate phosphorylation of MOR in a PKC-dependent manner. (A,B) SH-SY5Y cells treated with PMA (1 μM), E2 (1 μM), or G-1 (1 μM) for 30 min showed increased level of phosphorylated MOR (pMOR) as compared with the vehicle group. In the presence of the pan-PKC inhibitor (Ro 31-8820, Ro, 3 μM), E2 & G-1 failed to increase pMOR expression. (C) The averaged pMOR level (relative to beta -actin) in cells with different treatments. After detection of pMOR (A,B), the nitrocellulose membrane was stripped & re-blocked by 5% fat-free dry milk in TBST, followed by incubation with MOR primary antibody, then MOR band was detected. ∗∗P < 0.01, ∗∗∗P < 0.001, one-way ANOVA with Tukey’s post hoc test, averaged data from three to four independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31920512), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31180_rabbit-polyclonal-mu-opioid-r-oprm1-antibody-31020241539723.jpg "Western Blot: mu Opioid R/OPRM1 Antibody [NBP1-31180] - E2 & G-1 stimulate phosphorylation of MOR in a PKC-dependent manner. (A,B) SH-SY5Y cells treated with PMA (1 μM), E2 (1 μM), or G-1 (1 μM) for 30 min showed increased level of phosphorylated MOR (pMOR) as compared with the vehicle group. In the presence of the pan-PKC inhibitor (Ro 31-8820, Ro, 3 μM), E2 & G-1 failed to increase pMOR expression. (C) The averaged pMOR level (relative to beta -actin) in cells with different treatments. After detection of pMOR (A,B), the nitrocellulose membrane was stripped & re-blocked by 5% fat-free dry milk in TBST, followed by incubation with MOR primary antibody, then MOR band was detected. ∗∗P < 0.01, ∗∗∗P < 0.001, one-way ANOVA with Tukey’s post hoc test, averaged data from three to four independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31920512), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry KOR Antibody (387301) [Unconjugated]](https://images.novusbio.com/images/antibody/mab3895_human-kor-mab-clone-387301-immunocytochemistry-612022155719.jpg)
![Simple Western PAG1 Antibody (504004) [Unconjugated]](https://images.novusbio.com/images2/PAG1_MAB5285_Simple_Western_16616.jpg)
![Western Blot PAG1 Antibody (504004) [Unconjugated]](https://images.novusbio.com/images2/PAG1_MAB5285_Western_Blot_9455.jpg)
![Immunohistochemistry TFF2 Antibody (366508) [Unconjugated]](https://images.novusbio.com/images2/TFF2_MAB4077_Immunohistochemistry_21485.jpg)
![Western Blot ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Western_Blot_5097.jpg)
![Immunohistochemistry ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Immunohistochemistry_20696.jpg)
![Knockout Validated ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Knockout_Validated_22864.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")
